Assessment of the role of the renin-angiotensin system in cardiac contractility utilizing the renin inhibitor remikiren

British Journal of Pharmacology

Volumn 117, Issue 5, 1996, Pages 891-901

  Van Kats, J P ^a   Sassen, L M A ^a   Danser, A H J ^a   Polak, M P J ^a   Soei, L K ^a   Derkx, F H M ^a   Schalekamp, M A D H ^a   Verdouw, P D ^a,b  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Angiotension II; AT1 receptor antagonism; Cardiac contractility; L 158,809; Remikiren; Renin inhibition; Renin angiotensin system; Vasodilatation

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; NORADRENALIN; REMIKIREN; RENIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART FUNCTION; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART OUTPUT; HEART RATE; HEART WORK; HEMODYNAMICS; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SWINE; VASCULAR RESISTANCE; VASODILATATION;

EID: 0029939261     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15277.x     Document Type: Article

References (49)

1. ADMIRAAL, P.J.J., DERKX, F.H.M., DANSER, A.H.J., PIETERMAN, H. & SCHALEKAMP, M.A.D.H. (1990). Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension, 15, 44-55.
2. BIEN, J., SHARAF, B. & GEWIRTZ, H. (1991). Origin of anterior interventricular vein blood in domestic swine. Am. J. Physiol., 260, H1732-H1736.
3. CAMPBELL, D.J. (1987). Circulating and tissue angiotensin systems. J. Clin. Invest., 79, 1-6.
4. CHANG, R.S.L., SIEGL, P.K.S., CLINESCHMIDT, B.V., MANTLO, N.B., CHAKRAVARTY, P.K., GREENLEE, W.J., PATCHETT, A.A. & LOTTI, V.J. (1992). In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist J. Pharmacol. Exp. Ther., 262, 133-138.
5. CHRISTE, M.E., PERRETTA, A.A., LI, P., CAPASSO, J.M., ANVERSA, P. & RODGERS, R.L. (1994). Cilazapril treatment depresses ventricular function in spontaneously hypertensive rats. Am. J. Physiol., 267, H2050-H2057.
6. CLOZEL, J.-P & FISCHLI, W. (1993). Comparative effects of three different potent renin inhibitors in primates. Hypertension, 22, 9-17.
7. DANSER, A.H.J., KONING, M.M.G., ADMIRAAL, P.J.J., DERKX, F.H.M., VERDOUW, P.D. & SCHALEKAMP, M.A.D.H. (1992a). Metabolism of angiotensin I by different tissues in the intact animal. Am. J. Physiol., 263, H418-H428.
8. DANSER, A.H.J., KONING, M.M.G., ADMIRAAL, P.J.J., SASSEN, L.M.A., DERKX, F.H.M., VERDOUW, P.D. & SCHALEKAMP, M.A.D.H. (1992b). Production of angiotensin I and II at tissue sites in intact pigs. Am. J. Physiol., 263, H429-H437.
9. DANSER, A.H.J., VAN KATS, J.P., ADMIRAAL, P.J.J., DERKX, F.H.M., LAMERS, J.M.J., VERDOUW, P.D., SAXENA, P.R. & SCHALEKAMP, M.A.D.H. (1994). Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension, 24, 37-48.
10. DELABAYS, A., NUSSBERGER, J., PORCHET, M., WAEBER, B., HOYOS, P., BOGER, R., GLASSMAN, H., KLEINERT, H.D., LUTHER, R. & BRUNNER, H.R. (1989). Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension, 13, 941-947.
11. DE GASPARO, M., CUMIN, F., NUSSBERGER, J., GUYENNE, T.T., WOOD, J.M. & MENARD, J. (1989). Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br. J. Clin. Pharmacol., 27, 587-596.
12. DERKX, F.H.M., VAN DEN MEIRACKER, A.H., FISCHLI, W., ADMIRAAL, P.J.J., MAN IN'T VELD, A.J., VAN BRUMMELEN, P. & SCHALEKAMP, M.A.D.H. (1991). Nonparallel effects of renin inhibitor treatment on plasma renin activity and angiotensin I and II in hypertensive subjects. An assay-related artefact. Am. J. Hypertens., 4, 602-609.
13. DUNCKER, D.J., HEILIGERS, J.P.C., SAXENA, P.R. & VERDOUW, P.D. (1988). Nisoldipine and perfusion of post-stenotic myocardium in conscious pigs with different degrees of concentric stenosis. Br. J. Pharmacol., 94, 219-227.
14. ERDÖS, E.G. (1990). Angiotensin I converting enzyme and the changes in our concepts through the years. Hypertension, 16, 363-370.
15. FISCHLI, W., CLOZEL, J.-P., AMRANI, K.E., WOSTL, W., NEIDHART, W., STADLER, H. & BRANCA, Q. (1991). Ro 42-5892 is a potent orally active renin inhibitor in primates. Hypertension, 18, 22-31.
16. FISCHLI, W., CLOZEL, J.-P., BREU. V., BUCHMANN, S., MATHEWS, S., STADLER, H., VIEIRA, E. & WOSTL, W. (1994). Ciprokiren (Ro 44-9375). A renin inhibitor with increasing effects on chronic treatment. Hypertension, 24, 163-169.
17. FISHER, N.D.L., ALLAN, D., KIFOR, I., GABOURY, C.L., WILLIAMS, G.H., MOORE, T.J. & HOLLENBERG, N.K. (1994). Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans. Hypertension, 23, 44-51.
18. FOULT, J.-M., TAVOLARO, O., ANTONY, I. & NITENBERG, A. (1988). Direct myocardial and coronary effects of enalaprilat in patients with dilated cardiomyopathy: assessment by a bilateral intracoronary infusion technique. Circulation, 77, 337-344.
19. 3H]norepinephrine from rat atria. Hypertension, 24, 457-460.
20. HABER, E. (1985). Will renin inhibitors influence decision-making in antihypertensive therapy? J. Hypertens., 3 (suppl 3), S271-S273.
21. HARTMAN, J.C., WALL, T.M., HULLINGER, T.G. & SHEBUSKI, R.J. (1993). Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J. Cardiovasc. Pharmacol., 21, 996-1003.
22. JEUNEMAITRE, X., MENARD, J., NUSSBERGER, J., GUYENE, T.T., BRUNNER, H.R. & CORVOL, P. (1989). Plasma angiotensins, renin and blood pressure during acute renin inhibition by CGP 38560A in hypertensive patients. Am. J. Hypertens., 2, 819-837.
23. KIOWSKI, W., BEERMANN, J., RICKENBACHER, P., HAEMMERLI, R., THOMAS, M., BURKART, F. & MEINERTZ, T. (1994). Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic-heart failure. Assessment by acute renin and converting enzyme inhibition. Circulation, 90, 2748-2756.
24. KLEINERT, H.D. (1989). Renin inhibitors: discovery and development. An overview and perspective. Am. J. Hypertens., 2, 800-808.
25. KLEINERT, H.D., STEIN, H.H., BOYD, S., FUNG, A.K.L., BAKER, W.R., VERBURG, K.M., POLAKOWSKI, J.S., KOVAR, P., BARLOW, J., COHEN, J., KLINGHOFER, V., MANTEI, R., CEPA, S., ROSENBERG, S. & DENISSEN, J.F. (1992). Discovery of a well-absorbed, efficacious renin inhibitor, A-74273. Hypertension, 20, 768-775.
26. KOBAYASHI, M., FURAKAWA, Y. & CHIBA, S. (1978). Positive chronotropic and inotropic effects of angiotensin II in the dog heart. Eur. J. Pharmacol., 50, 17-25.
27. LINDPAINTNER, K. & GANTEN, D. (1991). The cardiac renin-angiotensin system. An appraisal of present experimental and clinical evidence. Circ. Res., 68, 905-921.
28. LINDPAINTNER, K., JIN, M., NIEDERMAJER, N., WILHELM, M.J. & GANTEN, D. (1990). Cardiac angiotensinogen and its local activation in the isolated perfused beating heart. Circ. Res., 67, 564-573.
29. LINDPAINTNER, K., WILHELM, M.J., JIN, M., UNGER, T., LANG, R.E., SCHOLKENS, B.A. & GANTEN, D. (1987). Tissue renin-angiotensin systems: focus on the heart. J. Hypertens., 5 (suppl 2), S33-S38.
30. LINZ, W., SCHAPER, J., WIEMER, G., ALBUS, U. & SCHOLKENS, B.A. (1992). Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood-pressure reduction: a one year study in rats. Br. J. Pharmacol., 107, 970-975.
31. MANGIAPANE, M.L., MURPHY, W.R., SCHELHORN, T.M., RAUCH, A.L. & HOLT, W.F. (1990). Hemodynamic effects of CP-80,974, an orally active renin inhibitor (abstract). FASEB J., 4, A748.
32. NUSSBERGER, J., BRUNNER, D.B., WAEBER, B. & BRUNNER, H.R. (1986). Specific measurement of angiotensin metabolites and in vitro generation of angiotensin II in plasma. Hypertension, 8, 476-482.
33. POULSEN, K. & JORGENSEN, J. (1974). An easy radioimmunological microassay of renin activity, concentration and substrate in human and animal plasma and tissues based on angiotensin trapping by antibody. J. Clin. Endocrinol. Metab., 39, 816-825.
34. RADDINO, R., PELA, G., POLI, E., MASCARO, F., MANCA, C. & VISIOLI, O. (1990). Different effects of captopril and other angiotensin converting enzyme inhibitors on cardiovascular preparations. Pharmacol, Res., 24, 163-174.
35. SASSEN, L.M.A., DUNCKER, D.J.G.M., GHO, B.C.G., DIEKMANN, H.W. & VERDOUW, P.D. (1990a). Haemodynamic profile of the potassium channel activator EMD 52692 in anaesthetized pigs. Br. J. Pharmacol., 101, 605-614.
36. SASSEN, L.M.A., SOEI, L.K., KONING, M.M.G. & VERDOUW, P.D. (1990b). The central and regional cardiovascular responses to intravenous and intracoronary administration of the phenyldihydropyridine elgodipine in anaesthetized pigs. Br. J. Pharmacol., 99, 355-363.
37. SCHAFFER, L.W., SCHORN, T.W., WINQUIST, R.J., STROUSE, J.F., PAYNE, L., CHAKRAVARTY, P.K., DE LASZLO, S.E., TENBROEKE, J., VEBER, D.F., GREENLEE, W.J. & SIEGL, P.K.S. (1990). Acute hypotensive responses to peptide inhibitors of renin in conscious monkeys: an effect on blood pressure independent of plasma renin inhibition. J. Hypertens., 8, 251-259.
38. SCHELLING, P., FISCHER, H. & GANTEN, D. (1991). Angiotensin and cell growth: a link to cardiovascular hypertrophy? J. Hypertens., 9, 3-15.
39. SIEGL, P.K.S., CHANG, R.S.L., MANTLO, N.B., CHAKRAVARTY, P.K., ONDEYKA, D.L., GREENLEE, W.J., PATCHETT, A.A., SWEET, C.S. & LOTTI, V.J. (1992). In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J. Pharmacol. Exp. Ther., 262, 139-144.
40. TREE, M., MACARTHUR, K., INGLIS, G., LECKIE, B., LEVER, A.F., MORTON, J.J. & SZELKE, M. (1989). Effects of the renin inhibitor H77 on angiotensin II, arterial pressure and cardiac function in conscious dogs: comparison with captopril. J. Hypertens., 7 (suppl 2), S51-S55.
41. URATA, H., HEALY, B., STEWART, R.W., BUMPUS, F.M. & HUSAIN, A (1989). Angiotensin II receptors in normal and failing human hearts. Circ. Res., 69, 54-66.
42. VAN DEN MEIRACKER, A.H., ADMIRAAL, P.J.J., DERKX, F.H.M., KLEINBLOESEM, C., MAN IN 'T VELD, A.J., VAN BRUMMELEN, P., MULDER, P. & SCHALEKAMP, M A.D.H. (1993). Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension. J. Hypertens., 11, 831-838.
43. VAN DEN MEIRACKER, A.H., ADMIRAAL, P.J.J., MAN IN 'T VELD, A.J., DERKX, F.H.M., RITSEMA VAN ECK, H.J., MULDER, P., VAN BRUMMELEN, P. & SCHALEKAMP, M.A.D.H. (1990). Prolonged blood pressure reduction by orally active renin inhibitor Ro 42,5892 in essential hypertension. Br. Med. J., 301, 205-210.
44. WEBER, M.A., NEUTEL, J.M., ESSINGER, I., GLASSMAN, H.N., BOGER, R.S. & LUTHER, R. (1990). Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Circulation, 81, 1768-1774.
45. WESSALE, J.L., CALZADILLA, S.V., BOYD, S.A., BAKER, W.R., STEIN, H.H., KOVAR, P.J., BARLOW, J., KLINGHOFER, V., MANTEI, R. & KLEINHERT, H.D. (1993a). Cardiovascular effects and hemodynamic mechanism of action of the novel, nonpeptide renin inhibitor A-74273 in dogs. J. Cardiovasc. Pharmacol., 22, 644-652.
46. WESSALE, J.L., KLEINERT, H.D., CALZADILLA, S.V., KOVAR, P.J. & ROSENBERG, S.H. (1993b). Effects of the renin inhibitor A-72517 on hemodynamics and cardiac function in sodium-depleted dogs. Am. J. Hypertens., 6, 514-521.
47. WOOD, J.M., BAUM, H.P., FORGIARINI, P., GULATI, N., JOBBER, R.A., NEISIUS, D. & HOFBAUER, K. (1989). Haemodynamic effects of acute and chronic renin inhibition in marmosets. J. Hypertens., 7 (suppl 2), S37-S42.
48. WOOD, J.M., MAH, S.C., BAUM, H.P., DE GASPARO, M., CUMIN, F., RUEGER, H. & NUSSBERGER, J. (1990). Evaluation of a potent inhibitor of subprimate and primate renins. J. Pharmacol. Exp. Ther., 253, 513-517.
49. ZUSMAN, R.M., BURTON, J., CHRISTENSEN, D., NUSSBERGER, J., DODDS, A. & HABER, E. (1983). Hemodynamic effects of a competitive renin inhibitory peptide in humans: evidence for multiple mechanisms of action. Trans. Assoc. Am. Physicians, 96, 365-374.